Research & Analysis: ERock, Inc. (NYSE: EROC)
ERock’s modular microgrids bridge data-center power gaps years before grid interconnects, with Meta and Anthropic projects filling capacity through early 2028.
ERock’s modular microgrids bridge data-center power gaps years before grid interconnects, with Meta and Anthropic projects filling capacity through early 2028.
$PPIH .. This is how some of these old school construction / infrastructure stocks have seen their P/Es re-rate higher over time. Investors love certainty, especially as short-term as they (we) are these days. See it all over the place, like what happened with $BDT.TO $ARE.TO https://t.co/Bufb8xvHOc
@AndrewRangeley Full $PRTH pitch here: https://t.co/P31Z8owE6q
@AndrewRangeley did a great pod with Zack from Buckley Capital on $PRTH. See the screenshot for a brief breakdown of the discussion. Full SSI write-up below👇 https://t.co/qhyD9esgF5
Q3 $OCC InfoArb was unusual, given the usual cryptic nature of mgmt commentary on calls: -Demand remains strong -August sales strong -Backlog continued to grow after July 31 -Adding employees and equipment to increase capacity -Sales from its Lightera collaboration have begun https://t.co/5Xv3Qvr3PY
Big day for the $PPIH family. First ever earnings call means we can start having fun. @InfoArbMonitor Q2 Delt-Sheet is ready. There's a lot of info for investors who weren't on the call to unpack... Let's stay ahead of the crowd and those who aren't willing to turn over rocks! https://t.co/zYszuSy2eZ
$RUM is a perception <> reality trade… A right wing version of YouTube or a sleeper AI/HPC pivot? 🤷♂️ https://t.co/uBcXByq8OS
$OKLO nicely timed insider sales by the dynamic husband + wife ceo/coo duo, the week prior to $1b offering announcement @jakedewitte @caorilne https://t.co/r0d0TREUOJ
Mosaic’s potash business generated $930 million after capital spending and closure cash in 2025, while phosphate operations consumed $207…
Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.
Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.
Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…
Group 1 Automotive and Lithia Motors divide two longtime value investors: David Abrams switched to Lithia in 2018, while Greg Alexander…
Atour Lifestyle combines an asset-light Chinese hotel franchise network with Atour Planet sleep-product sales, using guest rooms as product…
Moon River Moly’s updated Davidson PEA lifts after-tax NPV to $1.24 billion as flotation raises tungsten output 350% and cuts molybdenum…
Bumble agreed to a $6.05-per-share cash sale to Ithaca Holdings, 136% above its October 2 share price.
Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…
Webull expects perpetual futures and operating leverage to lift operating income from $114 million to nearly $400 million by 2030.
PYPD · long PolyPid, an $80 million Israeli biotech, fell nearly 30% despite solving a clinical problem.
Western Digital, Penguin Solutions and Millrose Properties lead a roundup of 12 lesser-followed stocks featured from Oct. 10 to Oct. 16.
Solstice, Albertsons, Brockhaus and GM anchor a 34-case survey of activism, buybacks, M&A and strategic reviews, led by Starboard’s…
Sagimet Biosciences' denifanstat enters a fully funded U.S. acne registration trial after Phase 3 results, with SGMT trading below cash and…
Silvercorp’s falling Ying grades, prolonged GC suspension, El Domo execution risk and Chaarat funding needs weaken its valuation despite…
Vicor’s $66.6 million in AI power-delivery royalties generated about $50 million of operating profit, eclipsing its module business as…
Inogen's $45 million buyback, debt-free balance sheet and cash equal to 61% of market value support a Buy case despite 3% 2026 growth…
CareCloud may attract a private-equity buyer after its Q3 call, with acquiring enough shares the main obstacle to a take-private deal.
Novo Nordisk has only floated hair loss, while Veradermics’ Phase 3 oral minoxidil data lead a field of licensing and takeover candidates.
Hain Celestial sold its North American snacks business for $115 million as declining sales and EBITDA left $558 million of secured debt…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.